CoChat

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study

Open access

The DOI matches its Crossref record, with a small difference in title or year; 22 of the 23 references it cites were found in a registry or an index.

Abstract

We performed a randomized dose-ranging study, double-blind for rivaroxaban doses and open-label for the comparator (low-molecular-weight heparin followed by vitamin K antagonists) to assess the optimal dose of rivaroxaban for the treatment of deep vein thrombosis. A total of 543 patients with acute deep-venous thrombosis received rivaroxaban 20, 30, or 40 mg once daily or comparator. Treatment lasted for 84 days. The primary efficacy outcome was the 3-month incidence of the composite of symptomatic venous thromboembolic complications and asymptomatic deterioration in thrombotic burden as assessed by comparison of ultrasound and perfusion lung scanning at day 84 with baseline. The main safety outcome was the composite of major bleeding and clinically relevant nonmajor bleeding. A total of 449 (83%) of the 543 patients could be included in the per-protocol population. The primary efficacy outcome occurred in 6.1%, 5.4%, and 6.6% of the rivaroxaban 20-, 30-, and 40-mg treatment groups, respectively, and in 9.9% of those receiving standard therapy. The main safety outcome occurred in 5.9%, 6.0%, and 2.2% of the rivaroxaban 20-, 30-, and 40-mg treatment groups, respectively, and in 8.8% of those receiving standard therapy. These results with simple fixed-dose oral regimens justify phase 3 evaluations (www.ClinicalTrials.gov no.NCT00395772).

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2008-05-160143

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Cited by

See all 343

Metadata

Authors
Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., & Segers, A.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Maastricht University Medical Centre (NL)
  • University of Perugia (IT)
  • King's College London (GB)
  • Flinders Medical Centre (AU)
  • BayerHealthCare AG, Wuppertal, Germany;
  • University of Oklahoma (US)
  • University Hospital Carl Gustav Carus (DE)
Venue
Blood
Published
2008-09-15
Volume
112
Issue
6
Pages
2242-2247
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2075359369
Cited by
342
References
23
Citations by year
2026: 1 · 2025: 4 · 2024: 5 · 2023: 11 · 2022: 7 · 2021: 10 · 2020: 22 · 2019: 14 · 2018: 12 · 2017: 11 · 2016: 18 · 2015: 25 · 2014: 28 · 2013: 37 · 2012: 22
FWCI
21.33
Type
journal article
Language
en
Licence
other-oa
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
rivaroxaban, deep vein thrombosis, factor Xa inhibitors, dose-ranging, venous thromboembolism, low molecular weight heparin, vitamin K antagonists, major bleeding, anticoagulation
MeSH terms
Rivaroxaban, Acute Disease, Adult, Aged, Aged, 80 and over, Antithrombin III, Dose-Response Relationship, Drug, Double-Blind Method, Female, Hemorrhage, Humans, Male, Middle Aged, Morpholines, Thiophenes, Ultrasonography, Treatment Outcome, Venous Thrombosis, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study. https://app.cochat.ai/papers/10.1182/blood-2008-05-160143
The paper
Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., & Segers, A. (2008). A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study. Blood. https://doi.org/10.1182/blood-2008-05-160143

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.